M&A
Ambrose Healthcare acquires AM-Pharma for up to €161M, gaining European base
October 20, 2026
Biotech
M&A
Key Facts
Signal Type
M&A
Industry
Biotech
Companies
Ambrose Healthcare, AM-Pharma, Chiesi, KalVista
Date
October 20, 2026
UK-based Ambrose Healthcare has acquired 100% of Dutch rare-disease biotech AM-Pharma for up to €161 million (~$181 million). The consideration includes an upfront payment plus milestones tied to commercialisation and royalties on future sales.
The deal adds ilofotase alfa, a Phase 2-ready enzyme replacement therapy for hypophosphatasia (HPP), as Ambrose's third pipeline asset. It also gives Ambrose its first European base in Utrecht, with regulatory, quality, and scientific infrastructure.
Ambrose Healthcare gains a pipeline asset and European infrastructure. AM-Pharma's stakeholders receive a milestone-based payout, and the Utrecht team becomes the foundation for Ambrose's EU operations.
For biotech services vendors, the immediate effect is a new European sponsor with a Phase 2-ready rare-disease asset. Clinical trial planning, regulatory engagement, and data management are likely to be mobilised as the pivotal study is designed.
The deal fits a wave of rare-disease consolidation, following Chiesi's 2026 purchase of KalVista for about $1.9 billion. Ambrose is making a smaller, earlier bet, buying a development-stage asset rather than a launched product.
Watch whether the planned pivotal study for ilofotase alfa delivers. The €161 million is largely contingent on milestones and royalties, not a fixed cash price, and the asset's case rests on Phase 1b biomarker data; a prior AM-Pharma Phase 3 sepsis trial failed.
Also watch for additional acquisitions. Ambrose's CEO said the company is built to develop clinical-stage assets with existing human safety data, signalling that further M&A of this type could follow.
Source:
DealroomGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
